摘要
丙型肝炎病毒(HCV)是丙型肝炎传染病的病原体,主要影响肝脏,就其严重性而言,一般会持续几周或直至终身。HCV的RNA基因组长9.6 kb,编码约3000个氨基酸的多聚蛋白,必须同时经过宿主和病毒蛋白酶的处理分别形成结构型(S)和非结构型(NS)蛋白。在此我们关注带有活化因子NS4A的丝氨酸蛋白酶NS3,即NS3/4A,一直被视为抗HCV治疗的最有吸引力的靶点之一。虽然没有可用的HCV疫苗,但仅是抗病毒药物就能够治愈约90%的患有丙型肝炎感染的病人。但另一方面,这些药物的疗效可能会由于过快的用药和交叉耐药性而受到阻碍。到目前为止,所有的HCV NS3/4A抑制剂主要是基于肽段的化合物,而这些化合物都源于NS3/4A底物的裂解产物。特别是大环肽已迅速成为一个经典的用于治疗HCV感染的NS3/4A蛋白酶抑制剂。本文综述了大环肽抗HCV NS3/4A蛋白酶的发展过程,以及临床上一些开发自线性肽段的重要抑制剂,这些抑制剂都是在过去的12年(2003-2015年)中通过所有的途径发现的,包括实验室合成的方法,虚拟筛选和基于结构的分子对接结构研究。我们强调设计背后的原理、构效关系研究,以及抑制剂的作用机制和大环肽对细胞的影响。
关键词: Hepatitis C virus
Current Medicinal Chemistry
Title:Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry
Volume: 23 Issue: 29
Author(s): Thanigaimalai Pillaiyar, Vigneshwaran Namasivayam, Manoj Manickam
Affiliation:
关键词: Hepatitis C virus
摘要: Hepatitis C virus (HCV) is a causative agent of hepatitis C infectious disease that primarily affects the liver, ranging in severity from a mild illness lasting a few weeks to a lifelong illness. The 9.6 kb RNA genome of HCV encodes approximately 3000 amino acid polyprotein that must be processed by host and viral proteases into both structural (S) and non-structural (NS) proteins, respectively. Targeting the serine protease NS3 with an activating factor NS4A, i.e., NS3/4A has been considered as one of the most attractive targets for the development of anti-HCV therapy. Although there is no vaccine available, antiviral medicines cure approximately 90% of the persons with hepatitis C infection. On the other hand, efficacy of these medications can be hampered due to the rapid drug and cross resistances. To date, all developed HCV NS3/4A inhibitors are mainly peptide-based compounds derived from the cleavage products of substrate. Specifically macrocyclic peptidomimetics have rapidly emerged as a classical NS3/4A protease inhibitors for treating the HCV infection. This review highlights the development of macrocyclic anti-HCV NS3/4A protease, as well as clinically important inhibitors developed from linear peptides, discovered during the last 12 years (2003-2015) from all sources, including laboratory synthetic methods, virtual screening and structure-based molecular docking studies. We emphasize the rationale behind the design, study of structure-activity relationships, and mechanism of inhibitions and cellular effect of the macrocyclic inhibitors.
Export Options
About this article
Cite this article as:
Thanigaimalai Pillaiyar, Vigneshwaran Namasivayam, Manoj Manickam , Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry, Current Medicinal Chemistry 2016; 23 (29) . https://dx.doi.org/10.2174/0929867323666160510122525
DOI https://dx.doi.org/10.2174/0929867323666160510122525 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamin-D in the Immune System: Genomic and Non-Genomic Actions
Mini-Reviews in Medicinal Chemistry Targeting CNS Transporters for Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Screening and In Vitro Evaluation of Potential Plasmodium falciparum Leucyl Aminopeptidase Inhibitors
Current Computer-Aided Drug Design CCL2 is Modulated by Cytokines and PPAR-γ in Anaplastic Thyroid Cancer
Anti-Cancer Agents in Medicinal Chemistry Common Features of the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease
Reviews on Recent Clinical Trials Blocking HIV-1 Replication by Targeting the Tat-Hijacked Transcriptional Machinery
Current Pharmaceutical Design Insulin Resistance-Induced Hypertension and a Role of Perivascular CGRPergic Nerves
Current Protein & Peptide Science Novel Direct Factor IIa and Xa Inhibitors: Mechanisms of Action and Preclinical Studies
Current Clinical Pharmacology Acute Coronary Syndromes: A Role of Immune System
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Non-Structural Proteins of RSV: Targeting Interferon Antagonists for Vaccine Development
Infectious Disorders - Drug Targets Chronic Diseases and COVID-19: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness
Current Stem Cell Research & Therapy Secretory Production of Recombinant Proteins in Escherichia coli
Recent Patents on Biotechnology Metabolomics and Its Practical Value in Pharmaceutical Industry
Current Drug Metabolism The Role of Diabetes in Molecular Pathogenesis of Cancer
Current Signal Transduction Therapy Snake Venom Phospholipases A2: A Novel Tool Against Bacterial Diseases
Current Medicinal Chemistry Toll-like Receptor 4 Gene Polymorphisms in Chinese Population After Allogeneic Hematopoietic Stem Cell Transplantation
Current Bioinformatics Macrophage Activation in Atherosclerosis: Pathogenesis and Pharmacology of Plaque Rupture
Current Vascular Pharmacology Glioma Targeting and Anti-glioma Effect of Interleukin 13 Peptide and RGD Peptide Dual Functionalized Nanoparticles
Current Pharmaceutical Biotechnology Forensic Toxicology and Pharmacogenomics: Hype or Hope For Higher Standards in Forensic Medicine?
Current Pharmacogenomics and Personalized Medicine